Publicaciones en las que colabora con Jordi Vila Estapé (43)

2024

  1. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 69-77

2023

  1. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  2. Correction: Epidemiological Changes and Improvement in Outcomes of Infective Endocarditis in Europe in the Twenty-First Century: An International Collaboration on Endocarditis (ICE) Prospective Cohort Study (2000–2012) (Infectious Diseases and Therapy, (2023), 12, 4, (1083-1101), 10.1007/s40121-023-00763-8)

    Infectious Diseases and Therapy

  3. Corrigendum: CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3(Front. Microbiol., (2022), 13, (918362), 10.3389/fmicb.2022.918362)

    Frontiers in Microbiology

  4. Epidemiological Changes and Improvement in Outcomes of Infective Endocarditis in Europe in the Twenty-First Century: An International Collaboration on Endocarditis (ICE) Prospective Cohort Study (2000–2012)

    Infectious Diseases and Therapy, Vol. 12, Núm. 4, pp. 1083-1101

  5. Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action

    World Journal of Emergency Surgery, Vol. 18, Núm. 1

2022

  1. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

    Frontiers in Microbiology, Vol. 13

  2. Hidden dissemination of carbapenem-susceptible OXA-48-producing Proteus mirabilis

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3009-3015

  3. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

2021

  1. Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

  2. Infective Endocarditis in Patients on Chronic Hemodialysis

    Journal of the American College of Cardiology, Vol. 77, Núm. 13, pp. 1629-1640

  3. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

  4. Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008–2017)

    Mayo Clinic Proceedings, Vol. 96, Núm. 1, pp. 132-146

  5. Uptake of ozenoxacin and other quinolones in gram-positive bacteria

    International Journal of Molecular Sciences, Vol. 22, Núm. 24

2020

  1. A Contemporary Picture of Enterococcal Endocarditis

    Journal of the American College of Cardiology, Vol. 75, Núm. 5, pp. 482-494

  2. Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA

    International Journal of Antimicrobial Agents, Vol. 56, Núm. 3

2019

  1. Microbiological profile of ozenoxacin

    Future Microbiology, Vol. 14, Núm. 9, pp. 773-787

  2. Mitral valve repair in infective endocarditis is not inferior to valve replacement: results from a Spanish nationwide prospective registry

    General Thoracic and Cardiovascular Surgery, Vol. 67, Núm. 7, pp. 585-593

  3. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or - resistant Staphylococcus aureus and Staphylococcus epidermidis

    PLoS ONE, Vol. 14, Núm. 10

  4. Ozenoxacin: a review of preclinical and clinical efficacy

    Expert Review of Anti-Infective Therapy, Vol. 17, Núm. 3, pp. 159-168